Genome-scale in vivo CRISPR screen identifies RNLS as a target for beta cell protection in type 1 diabetes.

MLA

Cai, Erica P., et al. “Genome-Scale in Vivo CRISPR Screen Identifies RNLS as a Target for Beta Cell Protection in Type 1 Diabetes.” Nature Metabolism, vol. 2, no. 9, Sept. 2020, pp. 934–45. EBSCOhost, https://doi.org/10.1038/s42255-020-0254-1.

APA

Cai, E. P., Ishikawa, Y., Zhang, W., Leite, N. C., Li, J., Hou, S., Kiaf, B., Hollister-Lock, J., Yilmaz, N. K., Schiffer, C. A., Melton, D. A., Kissler, S., & Yi, P. (2020). Genome-scale in vivo CRISPR screen identifies RNLS as a target for beta cell protection in type 1 diabetes. Nature Metabolism, 2(9), 934–945. https://doi.org/10.1038/s42255-020-0254-1

Chicago

Cai, Erica P, Yuki Ishikawa, Wei Zhang, Nayara C Leite, Jian Li, Shurong Hou, Badr Kiaf, et al. 2020. “Genome-Scale in Vivo CRISPR Screen Identifies RNLS as a Target for Beta Cell Protection in Type 1 Diabetes.” Nature Metabolism 2 (9): 934–45. doi:10.1038/s42255-020-0254-1.